Comparative effectiveness and implementation research: Directions for Neurology

There is an enormous unmet need for knowledge about how new insights from discovery and translational research can yield measurable, population‐level improvements in health and reduction in mortality among those having or at risk for neurological disease. Once several, well‐conducted randomized controlled trials establish the efficacy of a given therapy, implementation research can generate new knowledge about barriers to uptake of the therapy into widespread clinical care, and what strategies are effective in overcoming those barriers and in addressing health disparities. Comparative effectiveness research aims to elucidate the relative value (including clinical benefit, clinical harms, and/or costs) of alternative efficacious management approaches to a neurological disorder, generally through direct comparisons, and may include comparisons of methodologies for implementation. Congress has recently appropriated resources and established an institute to prioritize funding for such research. Neurologists and neuroscientists should understand the scope and objectives of comparative effectiveness and implementation research, their range of methodological approaches (formal literature syntheses, randomized trials, observational studies, modeling), and existing research resources (centers for literature synthesis, registries, practice networks) relevant to research for neurological conditions, to close the well‐documented evidence‐to‐practice gap. Future directions include building this research resource capacity, producing scientists trained to conduct rigorous comparative effectiveness and implementation research, and embracing innovative strategies to set research priorities in these areas. Ann Neurol 2012;71:732–742

[1]  A Eugene Washington,et al.  The Patient-Centered Outcomes Research Institute--promoting better information, decisions, and health. , 2011, The New England journal of medicine.

[2]  M. C. Gibbons,et al.  Preventing Recurrence of Thromboembolic Events through Coordinated Treatment in the District of Columbia , 2011, International journal of stroke : official journal of the International Stroke Society.

[3]  J. Tseng,et al.  Underutilization of therapy for hepatocellular carcinoma in the medicare population , 2011, Cancer.

[4]  William E. Cunningham,et al.  Randomized, Controlled Trial of an Intervention to Enable Stroke Survivors Throughout the Los Angeles County Safety Net to “Stay With the Guidelines” , 2011, Circulation. Cardiovascular quality and outcomes.

[5]  C. McCulloch,et al.  NIH Disease Funding Levels and Burden of Disease , 2011, PloS one.

[6]  R. Finkel,et al.  Widening gap in age at muscular dystrophy–associated death between blacks and whites, 1986–2005 , 2010, Neurology.

[7]  N. Dreyer,et al.  Registries for Evaluating Patient Outcomes: A User’s Guide , 2010 .

[8]  Heather M. Tavel,et al.  Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors Versus &bgr;-Blockers as Second-Line Therapy for Hypertension , 2010, Circulation. Cardiovascular quality and outcomes.

[9]  Elizabeth W Paxton,et al.  Kaiser Permanente National Total Joint Replacement Registry: Aligning Operations With Information Technology , 2010, Clinical orthopaedics and related research.

[10]  Michael D Hill,et al.  Stenting versus endarterectomy for treatment of carotid-artery stenosis. , 2010, The New England journal of medicine.

[11]  Francis S Collins,et al.  Using science to improve the nation's health system: NIH's commitment to comparative effectiveness research. , 2010, JAMA.

[12]  Kirsten Bibbins-Domingo,et al.  Projected effect of dietary salt reductions on future cardiovascular disease. , 2010, The New England journal of medicine.

[13]  D. Hirtz,et al.  Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. , 2010, The New England journal of medicine.

[14]  Alec B. O’Connor Building comparative efficacy and tolerability into the FDA approval process. , 2010, JAMA.

[15]  N. Dahodwala,et al.  Emerging Subspecialties in Neurology: Health services research , 2010, Neurology.

[16]  Eric E. Smith,et al.  Characteristics, Performance Measures, and In-Hospital Outcomes of the First One Million Stroke and Transient Ischemic Attack Admissions in Get With The Guidelines-Stroke , 2010, Circulation. Cardiovascular quality and outcomes.

[17]  Evelyn P Whitlock,et al.  White Paper on CTSA Consortium Role in Facilitating Comparative Effectiveness Research , 2010, Clinical and translational science.

[18]  F. Collins Opportunities for Research and NIH , 2010, Science.

[19]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[20]  A. Berg The CDC's EGAPP initiative: evaluating the clinical evidence for genetic tests. , 2009, American family physician.

[21]  S. Hauser,et al.  IOM task impossible: Set the agenda for neurological comparative effectiveness research , 2009, Annals of neurology.

[22]  D. Thurman,et al.  Disparities in epilepsy: Report of a systematic review by the North American Commission of the International League Against Epilepsy , 2009, Epilepsia.

[23]  Robert H Brook,et al.  Possible outcomes of comparative effectiveness research. , 2009, JAMA.

[24]  Vivian Gu,et al.  Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. , 2008, The New England journal of medicine.

[25]  Brian S Mittman,et al.  Overview of the VA Quality Enhancement Research Initiative (QUERI) and QUERI theme articles: QUERI Series , 2008, Implementation science : IS.

[26]  W. Meurer,et al.  Qualitative data collection and analysis methods: the INSTINCT trial. , 2007, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[27]  S. Horn,et al.  Practice-Based Evidence Study Design for Comparative Effectiveness Research , 2007, Medical care.

[28]  David F. Smith,et al.  The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial , 2007, The Lancet.

[29]  J. Westfall,et al.  Practice-based research--"Blue Highways" on the NIH roadmap. , 2007, JAMA.

[30]  E. Dooley National Institute of Neurological Disorders and Stroke , 2006 .

[31]  Robert G. Miller,et al.  Factors correlated with NPPV use in ALS , 2006, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[32]  S. Kasner,et al.  Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. , 2005, The New England journal of medicine.

[33]  Pamela W Duncan,et al.  Ethnic Disparities in Stroke: Epidemiology, Acute Care, and Postacute Outcomes , 2005, Stroke.

[34]  D. Altman,et al.  CONSORT statement: extension to cluster randomised trials , 2004, BMJ : British Medical Journal.

[35]  R. Teasell,et al.  Intensity of Aphasia Therapy, Impact on Recovery , 2003, Stroke.

[36]  Stephen B. Johnson,et al.  Central challenges facing the national clinical research enterprise. , 2003, JAMA.

[37]  N. Powe,et al.  Designing and evaluating interventions to eliminate racial and ethnic disparities in health care , 2002, Journal of general internal medicine.

[38]  J A Fleishman,et al.  Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. , 1999, JAMA.

[39]  Giovanni Parmigiani,et al.  The Stroke Prevention Policy Model: Linking Evidence and Clinical Decisions , 1997, Annals of Internal Medicine.

[40]  M A Hlatky,et al.  Variation among hospitals in coronary-angiography practices and outcomes after myocardial infarction in a large health maintenance organization. , 1996, The New England journal of medicine.

[41]  M. B. Brown,et al.  The Warfarin-Aspirin Symptomatic Intracranial Disease Study , 1995, Neurology.

[42]  F. Mosteller,et al.  A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. , 1992, JAMA.

[43]  J. Cramer,et al.  Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. , 1985, The New England journal of medicine.

[44]  R. Cicerone Initial National Priorities for Comparative Effectiveness Research , 2009 .

[45]  Sean,et al.  Research on the Comparative Effectiveness of Medical Treatments: Isues and Options for an Expanded Federal Role , 2007 .

[46]  Adrienne Y. Stith,et al.  Unequal treatment: confronting racial and ethnic disparities in health care. , 2003 .

[47]  R Whurr,et al.  Speech and language therapy for aphasia following stroke. , 2000, The Cochrane database of systematic reviews.

[48]  T. Imperiale Meta-analyses and large randomized, controlled trials. , 1998, The New England journal of medicine.

[49]  David R. Williams,et al.  Race and Health: A Multidimensional Approach to African American Health , 1995 .